Myditin (Pridinol Mesilate)

Pridinol mesilate, the active ingredient in Myditin, is a centrally acting muscle relaxant presented as an oral formulation for systemic use. It is employed to alleviate muscle spasm and associated musculoskeletal discomfort in adult patients.

GNH USA supplies Myditin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Myditin, a centrally acting muscle relaxant, is used to manage conditions involving involuntary muscle contraction and related pain. - Muscle spasm: reduces the frequency and intensity of involuntary muscle contractions. - Musculoskeletal pain: alleviates pain linked to muscle tension and strain. - Acute low back pain: helps relieve stiffness and discomfort in the lumbar region.

Adverse reactions to Myditin may vary in frequency and severity.

Common Side Effects: - Dry mouth: reduced salivation causing throat discomfort. - Drowsiness: mild sedation or increased sleepiness. - Dizziness: sensation of light‑headedness or unsteadiness. - Gastrointestinal upset: nausea or mild abdominal discomfort. - Blurred vision: temporary visual disturbances.

Serious or Rare Side Effects: - Cardiac arrhythmia: irregular heart rhythm requiring medical attention. - Severe allergic reaction: rash, swelling, or breathing difficulty. - Hepatic dysfunction: abnormal liver enzyme levels. - Extrapyramidal symptoms: involuntary muscle movements. - Urinary retention: difficulty in bladder emptying.

When prescribing Myditin, consider the following safety measures. - Assess renal and hepatic function: adjust use if impairment is present. - Monitor for signs of anticholinergic burden: especially in elderly patients. - Caution in patients with glaucoma: may exacerbate intra‑ocular pressure. - Avoid concurrent use with other CNS depressants: increased sedation risk. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Myditin may interact with other medications, influencing efficacy or safety.

Major Interactions (Avoid): - Other anticholinergic agents: may intensify anticholinergic side effects. - CNS depressants (e.g., benzodiazepines, opioids): risk of profound sedation.

Moderate Interactions (Monitor Closely):\n- Antihypertensive drugs: possible additive hypotensive effect. - Antihistamines: may increase drowsiness. - MAO inhibitors: potential for enhanced central effects.